Name | TC OT 39 |
---|---|
Synonyms |
(2S)-2-[(4-Methyl-1,4-diazepan-1-yl)carbonothioyl]-N-{2-methyl-4-[(1-methyl-4,10-dihydropyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]benzyl}-1-pyrrolidinecarboxamide
(2S)-2-[(4-methyl-1,4-diazepan-1-yl)carbothioyl]-N-{2-methyl-4-[(1-methyl-4,10-dihydropyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]benzyl}pyrrolidine-1-carboxamide 1-Pyrrolidinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)thioxomethyl]-, (2S)- MFCD28133368 TC OT 39 |
Description | TC OT 39 is a synthetic oxytocin analog, as well as a selective agonist of oxytocin receptor (OXTR, EC50=180 nM). TC OT 39 is also an Avprla vasopressin receptor antagonist with an Ki value of 330 nM. TC OT 39 exhibits sedative effects in mouse models[1]. |
---|---|
Related Catalog | |
Target |
Avprla vasopressin receptor:300 nM (Ki) Oxytocin Receptor:180 nM (EC50) |
In Vivo | TC OT 39 (50 mg/kg、75 mg/kg;腹腔注射;在 8-9 天内注射 4 次),在 50 mg/kg 的剂量下,显著减少 C57BL/6J 小鼠的大理石掩埋行为,并在 75 mg/kg 的剂量下显示出明显的镇静作用[1]。 大理石掩埋是基于啮齿动物掩埋物体的自然本能,常用于临床前研究以评估啮齿动物的焦虑样行为[1]。 |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C32H40N8O2S |
Molecular Weight | 600.777 |
Exact Mass | 600.299500 |
LogP | 2.00 |
Index of Refraction | 1.702 |